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New Findings
 What is the central question of this study?
The mechanism by which PAI-1R reduces proteinuria has not been previously explored.
 What is the main finding and its importance?
Using cultured podocytes and diabetic db/db mice, we show that, similar to the effects of
transforming growth factor-β1, PAI-1 directly injures podocytes. Reducing the increased
PAI-1 activity by PAI-1R in diabetic db/db mice, in fact, reduces podocyte injury, thereby
reducing albuminuria. Therefore, PAI-1R may provide an additional therapeutic effect in
slowing progression of diabetic nephropathy by maintaining podocyte integrity.
A mutant non-inhibiting plasminogen activator inhibitor type 1 (PAI-1), termed PAI-1R,
which reduces endogenous PAI-1 activity, has been shown to inhibit albuminuria and reduce
glomerulosclerosis in experimental diabetes. The mechanism of the reduction of albuminuria
is unclear. This study sought to determine whether the administration of PAI-1R protected
podocytes from injury directly, thereby reducing albuminuria in the db/db mouse, a model
of type 2 diabetes. Untreated uninephrectomized db/db mice developed significant mesangial
matrix expansion and albuminuria at week 22 of age, associated with segmental podocyte
foot-process effacement, reduction of renal nephrin, podocin and zonula occludin-1 production
and induction of renal desmin and B7-1 generation. In contrast, treatment with PAI-1R at
0.5 mg (kg body weight)−1 i.p., twice daily from week 20 to 22, reduced glomerular matrix
accumulation, fibronectin and collagen production and albuminuria by 36, 62, 65 and 31%,
respectively (P < 0.05), without affecting blood glucose level or body weight. Podocyte
morphology and protein markers were also significantly attenuated by PAI-1R administration.
Importantly, recombinant PAI-1 downregulated nephrin and zonula occludin-1 but increased
desmin and B7-1mRNA expression and protein production by podocytes in vitro, similar to the
effects of transforming growth factor-β1. These observations provide evidence that PAI-1, in a
manner similar to transforming growth factor-β1, directly induces podocyte injury, particularly
in the settingofdiabetes,where elevatedPAI-1maycontribute to theprogressionof albuminuria.
Reducing the increased PAI-1 activity by administration of PAI-1R, in fact, reduces podocyte
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injury, thereby reducing albuminuria. Therefore, PAI-1R provides an additional therapeutic
effect in slowing the progression of diabetic nephropathy via the protection of podocytes.
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Introduction
Diabetes is the leading cause of end-stage renal disease,
and almost half of new end-stage renal disease patients
have diabetes (Molitch et al. 2004). Despite the use of
angiotensin-converting enzyme inhibitors or angiotensin
receptor blockers (Brenner et al. 2001; Parving et al. 2001),
progression of diabetic nephropathy is common. Hence,
it is important to identify other interventions that might
retard the progression of diabetic nephropathy.
Recently, plasminogen activator inhibitor type 1
(PAI-1) has emerged as a powerful fibrogenic mediator
in kidney diseases, including diabetic nephropathy (Eddy
& Fogo, 2006; Brown, 2010; Ghosh & Vaughan, 2012).
Enhanced glomerular expression of PAI-1 has been
reported in both human and animal models of diabetes
(Paueksakon et al. 2002; Huang et al. 2008). Besides
diabetes, increased deposition of PAI-1 in the kidney has
been demonstrated in most other human kidney diseases
(Rondeau et al. 1990; Shihab et al. 1995; Yamamoto et al.
1996, 1999; Grandaliano et al. 2000; Lee et al. 2001).
The elevated expression of PAI-1 is found in podocytes,
in endothelial and mesangial cells of the glomeruli, in
proximal tubular epithelial cells and in small arteries and
fibroblast cells in the interstitium (Keeton et al. 1993).
Importantly, genetic PAI-1 deficiency has been shown
to be protective in experimental diabetic nephropathy,
five-sixth nephrectomy, crescentic anti-GBM nephritis
and the spontaneous renal fibrosis that develops in mice
that overexpress transforming growth factor-β (TGFβ;
Oda et al. 2001; Krag et al. 2005; Nicholas et al. 2005; Eddy
& Fogo, 2006). In contrast, the renal fibrosis is worse in
PAI-1-overexpressingmice (Matsuo et al. 2005). Together,
these observations strongly implicate tissue PAI-1 in the
renal fibrotic process.
The profibrotic actions of PAI-1 have not been
completely elucidated. Plasminogen activator inhibitor
type 1 possesses two distinct functions that could
mediate its profibrotic effects alone or in combination,
which are an antiprotease activity that inhibits the
generation of plasmin and a vitronectin-binding ability
that interferes with cell adhesion to this extracellular
matrix protein (Huang & Noble, 2007). As the primary
physiological inhibitor of urokinase (uPA) and tissue-type
plasminogen activator, PAI-1 controls the formation
and activity of plasmin and, consequently, promotes
fibrin deposits and accumulation of fibrotic matrix.
The binding of PAI-1 to vitronectin could also be
important in the pathogenesis of fibrosis. When bound
to vitronectin, the antiprotease activity of PAI-1 is
significantly stabilized (Podor et al. 2000). The binding
of PAI-1 to vitronectin also blocks the interactions of
vitronectin with cell-surface integrin required for cellular
motility andwith the receptor for cell-bound uPA (uPAR).
Furthermore, the binding of PAI-1 to vitronectin induces
epithelial-to-mesenchymal transition in epithelial cells by
modulating their interactionwith the extracellularmatrix,
a process that is involved in tissue fibrosis (Scaffidi et al.
2001; Vial & McKeown-Longo, 2008; Senoo et al. 2010).
Whether the properties of PAI-1 observed in vitro are also
operative in diseased subjects or animal models remains
unclear.
In order to understand the actions of PAI-1 further
and to develop a potential therapeutic agent that inhibits
PAI-1 in vivo, a non-inhibitory mutant PAI-1 (PAI-1R)
was designed (Stefansson et al. 2001). This PAI-1Rmutant
does not inhibit uPA or tissue-type plasminogen activator,
but it retains the ability to bind vitronectin, thereby
decreasing the availability of vitronectin for PAI-1 and
effectively shortening its half-life. The administration of
PAI-1R to nephritic rats and diabetic db/dbmice increased
glomerular plasmin generation and reduced proteinuria
and glomerulosclerosis (Huang et al. 2003, 2008). Using
the plasminogen/plasmin blocker tranexamic acid, we
further observed that the therapeutic effect of PAI-1R on
glomerular extracellular matrix accumulation was largely
mediated through plasmin, because this effect was blocked
by cotreatment with tranexamic acid (Huang et al. 2006).
However, the effect of PAI-1R on the reduction
of proteinuria was not affected by blocking plasmin
generation, suggesting that PAI-1R has multiple
therapeutic actions on the measures of disease severity.
Conversely, elevated PAI-1 may have multiple actions
on the induction and progression of kidney disease.
It is likely that PAI-1 may act as a direct cause of
proteinuria independent of plasmin generation, which
could be prevented by inhibition of PAI-1. This notion
was strengthened by the observations that PAI-1 deletion
significantly reduced the severity of proteinuria in diabetes
(Nicholas et al. 2005; Collins et al. 2006; Lassila et al.
2007). It has been shown that proteinuria is often the
result of podocyte injury in human diseases and animal
models, especially in diabetes (Yu et al. 2005; Shankland,
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2006; Ziyadeh & Wolf, 2008). Thus, we postulate that
PAI-1 plays a role in podocyte injury and proteinuria. We
further hypothesize that PAI-1R reduces proteinuria by
the amelioration of podocyte injury via PAI-1 inhibition.
To test our hypothesis, we examined whether PAI-1
directly damagedpodocytes in cell culture anddetermined
the therapeutic efficacy of PAI-1R on podocyte injury
in a murine model of uninephrectomized diabetic
nephropathy.
Methods
Reagents
Unless otherwise indicated, materials and chemicals were
obtained from Sigma-Aldrich (St Louis, MO, USA).
The recombinant human PAI-1R and active stable PAI-1
have been described previously (Huang et al. 2009) and
were purified as described (Kvassman & Shore, 1995).
Study 1: therapeutic effects of PAI-1R on
diabetes-associated podocyte injury in db/db mice
Animals. Diabetic male db/db mice (BKS.Cg-Dock7m
+/+ Leprdb/J homozygotes) and their littermate male
db/m mice were obtained from the Jackson Laboratory
(Bar Harbor, ME, USA) and housed in accordance with
the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health (NIH
publication no. 85-23, revised 1996). The experimental
protocols were approved by the Animal Care Committee
at theUniversity of Utah. The db/dbmicewere determined
to be diabetic by the vendor on the basis of the appearance
of obesity at 5 weeks of age and were demonstrated
to be hyperglycaemic in our laboratory at week 7. Mice
were subjected to right uninephrectomy under general
anaesthesia induced by inhalation of 2.5% isoflurane
through a complete anaesthesia system (VetEquip
IMPAC6; VetEquip Inc., Pleasanton, CA, USA) at week 8
to hasten the development of diabetic nephropathy as
described previously (Huang et al. 2008). The db/m mice
were subjected to uninephrectomy at week 8 to serve
as the operation control. Our previous work on model
development showed that uninephrectomized diabetic
db/db mice developed overt nephropathy by 18 weeks of
age, and disease progression was remarkable between 18
and 22 weeks of age, determined by expansion of the
mesangium and significant albuminuria (Huang et al.
2008). In the present study, this model was used to
determine the impact of PAI-1R on podocyte injury from
20 to 22 weeks of age.
Experimental design. Groups of eight or nine
uninephrectomized mice were assigned and treated
at 20 weeks of age as follows: untreated non-diabetic db/m
mice (n = 9) as healthy control animals; diabetic db/db
mice treated with PBS by I.P. injection from week 20 to 22
(n= 8) as disease control animals; and diabetic db/dbmice
treated with 0.5 mg (kg body weight)−1 PAI-1R injected
I.P., twice daily, from week 20 to 22 (n = 8; the effective
dose of PAI-1R was determined previously, see Huang
et al. 2008). The blood glucose level and glycosylated
haemoglobin (HbA1c) level were monitored in tail blood
samples by using a blood glucose metre (Glucometer
Elite XL; Bayer Healthcare, Elkhart, IN, USA) and the
DC 2000+ HbA1C kit (Bayer Healthcare), respectively.
Collection of urine for 24 h was carried out for each
mouse after placement in metabolic cages. Urine albumin
was measured using the DC2000+ microalbumin reagent
kit (Bayer Healthcare). Regarding the reproducibility of
this assay, the coefficients of variance were <3% when the
same sample was measured three times consecutively.
Mice were killed under isoflurane anaesthesia in
accordance with the US National Institutes of Health
Guide for the Care and Use of Laboratory Animals.
Briefly, general anaesthesia was induced by inhalation of
2.5% isoflurane through a complete anaesthesia system
(VetEquip IMPAC6; VetEquip Inc., Pleasanton, CA,USA).
When mice were deeply anaesthetized as determined
by absence of the toe-pinch reflex, blood samples were
obtained by cardiac puncture, and the kidneys were
perfused through theheartwith coldPBSand then excised.
Mice died of massive blood loss. The renal cortex was
harvested by dissection and saved for further analysis as
described previously (Huang et al. 2008). Briefly, three
pieces of cortexwere either snap-frozen in 2-methylbutane
at –80°C or fixed in 10% neutral-buffered formalin
for immunohistological examination or fixed in 2.5%
glutaraledhyde and 0.1 M sodium cacodylate buffer at
4°C for electron microscopic examination. Other pieces
of cortex were treated with TRIzolTM Reagent (GibcoBRL,
Gaithersburg, MD, USA) for isolation of RNA or treated
with 100 mM NaCl and 20 mM Hepes to be sonicated for
30 s, three times on ice and centrifuged at 13,100 g for
15 min at 4°C. The supernatant from the sonication was
then collected and stored at –80°C for fibronectin (FN)
ELISA (Huang et al. 2008) and protein measurement by a
BCA protein assay kit (Pierce, Rockford IL, USA). The
total collagen level in renal cortex was determined by
a colorimetric method according to the manufacturer’s
instructions (Biocolor Ltd, Carrickfergus, UK), in which
the Sirius Red dye binds to the side-chains of amino acids
found in collagen.
Histological analyses. Formalin-fixed renal cortex
tissues were subsequently embedded in paraffin.
Three-micrometre-thick sections were cut from the tissue
blocks and stained with periodic acid–Schiff. The periodic
C© 2014 The Authors. Experimental Physiology C© 2014 The Physiological Society
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acid–Schiff-positive glomerular matrix was quantified
in a blinded fashion by a computer-assisted method as
previously described (Huang et al. 2008). At least 20
glomeruli from each mouse were assessed. The matrix
surface area in the mesangium was normalized by that
of the total glomerular tuft, where the percentage of
mesangial matrix occupying each glomerulus was rated
on a 0–4 scale (0= 0, 1= 25, 2= 50, 3= 75 or 4= 100%),
as described previously (Huang et al. 2008).
Immunofluorescent staining for nephrin and podocin
was performed on frozen sections. The polyclonal goat
anti-nephrin IgG and the polyclonal goat anti-podocin
IgG (Santa Cruz Biotechnology, Inc., Santa Cruz, CA,
USA)were used as the primary antibodies. The rhodamine
(TRITC)-conjugated donkey anti-goat IgG (reacts with
both heavy and light chains; Jackson ImmunoResearch
Laboratories Inc., West Grove, PA, USA) was used as
the secondary antibody. Intraglomerular positive staining
of both molecules was also quantified separately in a
blinded fashion by a computer-assisted method. Briefly,
images (×400 magnification) of 20 random glomeruli
per slide were captured using a Nikon D50 digital
camera (Inkle’s-Ritz Camera, www.ritzcamera.com, Salt
Lake City, UT, USA; Nikon Capture 4 version 4.3, Nikon
Inc., Melville, NY, USA), and the total staining intensity in
each glomerulus was quantified using a computer-assisted
colour image analysis system (ImageJ 1.38 for Windows;
National Institutes of Health http://rsb.info.nih.gov;
Abramoff et al. 2004). The results were expressed as the
ratio of the staining intensity in the experimental groups
to that in the normal glomeruli.
Transmission electron microscopic examination. Gluta-
raledhyde-fixed renal cortex tissues were further processed
with OsO4 and Epon 812. Ultrathin sections were cut and
stained with uranyl acetate and lead citrate. Specimens
were placed on copper grids and examined in an electron
microscope (JEOL JEM-1010,Tokyo, Japan). Foot-process
density was calculated by dividing the number of foot
processes by the glomerular basement membrane (GBM)
length (Zheng et al. 2008).
Western blot analysis. Equal amounts of renal cortex
tissue (15 mg) from each mouse of each group
were homogenized in lysis buffer (Cell Signaling
Technology, Inc., Beverly, MA, USA) with 1%
octylphenoxypolyethoxyethanol (Nonidet P-40), 1 mM
phenylmethylsulfonyl fluoride and one tablet per
5 ml protease inhibitor mix (Complete, Mini; Roche
Diagnostics Corporation, Indianapolis, IN, USA). Protein
samples fromeight or ninemice of each groupwere pooled
for further examination.
For Western blot analysis, protein samples (20
μg each) were subjected to SDS-PAGE in 4–12%
gradient gels (Invitrogen, Carlsbad, CA, USA) and
immunblotted onto immobilon-P transfer membranes
(Millipore Corporation, Bedford, MA, USA). Desmin
and B7-1 were assessed on the Western blots
using mouse monoclonal anti-desmin IgG2a (Santa
Cruz Biotechnology, Inc.) and rabbit monoclonal
anti-B7-1/CD80 IgG (OriGene Technologies, Inc.,
Rockville, MD, USA). The immunostaining band
was visualized and quantified as described previously
(Huang et al. 2008). Desmin and B7-1 protein levels
were corrected by the densitometric intensity of the
glyceraldehyde 3-phosphate dehydrogenase (GAPDH;
using goat anti-GAPDH IgG antibody; GenScript,
Piscataway,NJ,USA) orβ-actin (usingmousemonoclonal
anti-β-actin IgG) in each loading. For comparison, this
ratiowas set at unity for normal control samples, andother
lanes on the same gel were expressed as the fold-change
over this value. Three blots were performed for each
primary antibody.
Preparation of RNA and real-time RT-PCR. Total RNA
was extracted from renal cortex tissue using TRIzolTM
Reagent (GibcoBRL) according to the manufacturer’s
instructions. Two micrograms of total RNA were reverse
transcribed using the Superscript III first-strand synthesis
system for RT-PCR kit (Invitrogen). Real-time RT-PCR
was performed using the SYBR green dye I (Applied
Biosystems, Foster City, CA, USA) and the ABI 7900
Sequence Detection System (Applied Biosystems) as
described previously (Huang et al. 2008). Samples were
run in triplicate in separate tubes to permit quantification
of the target gene normalized to β-actin. Sequences of
primers used are listed in Table 1. The specificity of the
PCR products was confirmed on a 1.5% agarose gel by
showing a specific single band with the expected size.
Study 2: effect of wild-type PAI-I on cultured
podocytes
Cell culture. Conditionally immortalized mouse
podocytes were kindly provided by Dr Peter Mundel
(Massachusetts General Hospital and Harvard Medical
School). These cells were cultured and induced to
differentiate as described previously (Reiser et al. 2004).
Briefly, podocytes were cultured in permissive conditions
(33°C) in RPMI-1640 supplemented with 10% fetal
calf serum, penicillin–streptomycin and interferon-γ
(all from Invitrogen). Differentiation was induced by
thermoshift to 37°C without interferon-γ in type I
collagen-coated six-well plates (Fisher Science Education,
Hanover Park, IL, USA) before experimental treatment.
All experiments were performed with cells that had been
allowed to differentiate for at least 14 days. Podocytes
between passages 10 and 15 were used for all experiments.
C© 2014 The Authors. Experimental Physiology C© 2014 The Physiological Society
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Table 1. Primers used for real-time RT-PCR
Gene Primer Location (complementary to nucleotides) Sequence 5′–3′
Mouse nephrin Forward 4344–4363 AGATTTTGGGTTGCAGGTTG
(NM 019459) Reverse 4476–4495 TGACCCATCTTTCCAGTTCC
Mouse zonula occludin-1 Forward 5975–5994 GGGGTGCATTTGAGTTCTGT
(NM 009386.1) Reverse 6219–6238 ACATGCTTTGGTGTCCTTCC
Mouse desmin Forward 1374–1393 CAAAGGGGTTCTGAAGTCCA
(NM 010043.1) Reverse 1552–1571 GAAAAGTGGCTGGGTGTGAT
Mouse B7-1 Forward 297–316 CCATGTCCAAGGCTCATTCT
(NM 009855.2) Reverse 480–499 TTCCCAGCAATGACAGACAG
Mouse β-actin Forward 857–876 GCTCTTTTCCAGCCTTCCTT
(NM 007393.2) Reverse 1132–1151 TGATCCACATCTGCTGGAAG
Effect of PAI-1 on podocyte injury. To examine the effect
of PAI-1 on podocyte injury, differentiated podocytes
were rendered quiescence in serum-free medium for 24 h,
then incubated with 150 nM of recombinant active stable
human PAI-1 for various times or incubated for 24 h
in incremental concentrations of PAI-1 (Huang et al.
2009). Podocytes treated with serum-free medium only
or with 2 ng ml−1 TGFβ1 (R&D, Minneapolis, MN,
USA) for 24 h served as normal and positive controls,
respectively. After incubation, the podocytes were washed
with ice-cold PBS. Total cellular RNA or protein was
isolated from the podocytes as described previously for
the analyses of the mRNA and protein expression of
podocyte-associated molecules by real-time RT-PCR and
Western blotting respectively (Huang et al., 2007). The
rabbit polyclonal anti-nephrin antibody (TA306037) and
rabbit polyclonal anti-zonula occludin-1 (ZO-1) antibody
(61-7300) were obtained from OriGene Technologies and
Invitrogen, respectively. All experiments were performed
at least three times in duplicate wells.
Statistical analyses
Data are expressed as means ± SD. The disease-induced
increase in a variable was defined as the mean value
for the disease control group minus the mean value
of the normal control group. The percentage of
reduction in disease severity in a treated group was
calculated as described previously (Huang et al. 2008).
Statistical analyses of differences between the groups
were performed by one-way ANOVA and subsequent
Student–Newman–Keuls or Dunnett testing for multiple
comparisons. A value of P < 0.05 was considered
statistically significant.
Results
Study 1: therapeutic efficacy of PAI-1R
Systemic parameters. There was no significant difference
in survival rate among the groups of non-diabetic db/m
mice, diabetic db/db mice treated with PBS and diabetic
db/db mice treated with PAI-1R. The baseline and final
parameters of the three groups of mice are presented in
Table 2. The body weights of db/db mice at 20 weeks
of age were significantly greater than the corresponding
values in db/m control animals. There was no significantly
change in body weight from week 20 to 22 in db/dbmice.
Diabetic mice remained hyperglycaemic throughout the
experimental period, as indicated by blood glucose and
glycosylated haemoglobin levels. The PAI-1R treatment
had no effect on body weight or blood glucose levels in the
db/dbmice.
At the beginning of intervention (20 weeks of age),
urinary albumin excretion of db/db mice in both groups
treated with or without PAI-1R was similar and was
significantly higher compared with db/m mice. Albumin
excretion stayed high between weeks 20 and 22 in
PBS-treated db/db mice. The PAI-1R treatment, in
fact, lowered the urinary albumin excretion by 31.4%
(359.5 ± 45.3 versus 247.4 ± 19.1 μg day−1; P < 0.05).
Glomerular histology. At the end of the study
(22 weeks), the glomeruli of db/db mice demonstrated
increased accumulation of periodic acid–Schiff-positive
extracellularmatrix proteins in themesangium, compared
with glomeruli of db/m mice (Fig. 1A and B).
Treatment with PAI-1R ameliorated extracellular matrix
deposition from the diabetic glomeruli by 36.3%
(P < 0.05).
Collagen and FN levels in renal cortex. The levels of both
collagen and FN, two major components of glomerular
extracellular matrix, were quantified in the renal cortex.
Consistent with the accumulation of glomerular periodic
acid–Schiff-positive extracellular matrix, levels of FN
and collagen were significantly increased in db/db
mice at week 22. The PAI-1R treatment reduced the
disease-induced increases in protein levels of FN and
collagen by 62.5 and 67.7%, respectively (P< 0.05; Fig. 1C
and D).
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Table 2. Parameters of the experimental groups of mice
Parameter db/m (n = 9) db/db (n = 8) db/db-PAI-lR (n = 8)
Body weight, initial (g) 24.5 ± 0.8 43.1 ± 6.0∗ 46.0 ± 3.3∗
Body weight, final (g) 25.1 ± 1.3 43.1 ± 5.6∗ 42.4 ± 3.5∗
Plasma glucose, initial (mg dl−1) 106.2 ± 16.8 512.0 ± 96.8∗ 553.0 ± 59.1∗
Plasma glucose, final (mg dl−1) 98.1 ± 43.7 560.0 ± 65.9∗ 595.4 ± 5.9∗
Glycosylated haemoglobin (%) 3.8 ± 0.2 9.8 ± 2.4∗ 10.2 ± 2.2∗
Urinary albumin excretion, initial (μg day−1) 7.4 ± 0.5 345.8 ± 0.6∗ 359.5 ± 45.2∗
Urinary albumin excretion, final (μg day−1) 6.1 ± 1.3 356.9 ± 3.5∗ 247.4 ± 19.1∗†‡
Non-diabetic (db/m) or diabetic mice (db/db) were treated for 2 weeks with either PBS or PAI-1R between 20 and 22 weeks of age.
∗P < 0.05 versus db/m; †P < 0.05 versus db/db; ‡P < 0.05 versus db/db-PAI-R at 20 weeks of age.
Electronic microscopy of podocyte ultrastructure. As
shown in Fig. 2A–C, segmental podocyte foot-process
effacement and a decrease in foot-process density were
evident in the glomeruli fromdiabeticmice at 22 weeks, in
comparison to glomeruli from non-diabetic mice (db/db
versus db/m, 1.56± 0.35 versus 3.42± 0.34, P< 0.05). The
PAI-1R treatment effectively restored foot-process density
(PAI-1R versus db/db, 2.83 ± 0.67 versus 1.56 ± 0.35,
P < 0.05). The changes of the podocyte foot process can
be seen clearly in the high-resolution images (Fig. 2D–F).
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Figure 1. In vivo effect of mutant plasminogen activator inhibitor type 1 (PAI-1R) on glomerular matrix
protein accumulation
A, representative photomicrographs (at original magnification ×400) of glomeruli at 22 weeks from
normal control mice (db/m), diabetic db/db mice treated with PBS (db/db) and diabetic db/db mice
treated with mutant plasminogen activator inhibitor type 1 (db/db-PAI-1R). Graphical representation of
the mean periodic acid–Schiff staining scores (B). Fibronectin (FN; C) and total collagen (D) of each group
are also shown. ∗P < 0.05 versus db/m. #P < 0.05 versus db/db.
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Expression of podocyte slit-diaphragm-associated
proteins. In order to confirm the protective effects of
PAI-1R on podocyte injuries observed using electronic
microscopy, the podocyte slit-diaphragm-associated
proteins nephrin and podocin were assessed by
immunofluorescent staining. As shown in Fig. 3, non-
diabetic db/m mice showed intense and linear staining
for both nephrin and podocin along the capillary in the
glomeruli. In contrast, diabetes resulted in an attenuation
of staining by 48.4% for nephrin and 36.9% for podocin
(P < 0.05) in the glomeruli of db/db mice at 22 weeks
of age. The administration of PAI-1R reduced the loss of
podocyte-specific nephrin and podocin staining by 58.6
and 73.7%, respectively (P < 0.05).
Figure 2. In vivo effect of PAI-1R on podocytes assessed by transmission electron microscope
Representative photomicrographs of glomerular podocytes obtained at 22 weeks from a normal control
mouse (db/m; A), a diabetic db/db mouse treated with PBS (db/db; B) and a diabetic mouse treated with
PAI-1R (db/db-PAI-1R; C). The podocyte foot process is indicated by an arrow. The zoom images (D–F) are
shown below the original photographs. Scale bar in A and C represents 1 μm and represents 2 μm in B.
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Figure 3. Effect of PAI-1R on immunofluorescent staining for glomerular nephrin and podocin atweek 22
Representative photomicrographs (original magnification ×400) of the glomeruli obtained at 22 weeks
from a normal control mouse (db/m), a diabetic db/db mouse treated with PBS (db/db) and a diabetic
db/db mouse treated with PAI-1R (db/db-PAI-1R). Graphical representations of the mean nephrin and
podocin staining scores of each group are shown on the right. ∗P < 0.05 versus db/m. #P < 0.05 versus
db/db.
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Figure 4. Effect of PAI-1R on desmin and B7-1 production in
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A, representative Western blots showing desmin and B7-1
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Expression of markers of podocyte injury. By Western
blotting, we observed that the protein levels of desmin in
renal cortex tissues, a conventional marker for podocyte
injury, were upregulated by 190% in diabetic db/db mice
(P < 0.05), as shown in Fig. 4. The PAI-1R treatment
reversed the disease-induced increase of desmin protein.
In addition, it has been shown that B7-1 is synthesized
in podocytes in response to split-diaphragm protein
rearrangement and foot-process effacement, and serves as
another marker of injury (Reiser et al. 2004). As shown
in Fig. 4, B7-1 protein levels were markedly increased
in diabetic renal tissue in db/db mice. Although we
could not confirm whether the elevated production of
desmin and B7-1 was from podocytes, the changes of
both desmin and B7-1 were consistent with the changes
of the two slit-diaphragm-associated proteins nephrin
and podocin shown in Fig. 3, which may indicate that
increased renal production of desminin and B7-1 could
somehow be related to podocyte injury in diabetic db/db
mice. Consistent with the results for nephrin and podocin,
PAI-1R treatment also successfully reduced the elevated
B7-1protein expression indb/dbmiceby58.3%(P<0.05).
In agreement with protein levels, over 50% mRNA
expression of nephrin was lost in diabetic db/db mice at
week 22, compared with that of db/m control animals.
The PAI-1R treatment rescued 71.5% of the reduction of
nephrin mRNA levels in diabetic renal tissue (Fig. 5A).
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In contrast, mRNA expression of desmin and B7-1 was
markedly increased in diabetic renal tissue by 14- and
20-fold, respectively (P < 0.05), compared with that
found in normal renal tissue (P < 0.05). The PAI-1R
treatment reversed the increased mRNA expression of
desmin and B7-1 (Fig. 5C and D), similar to the response
of the corresponding proteins. We also measured mRNA
expressionof the tight junctionproteinZO-1 inpodocytes.
Unsurprisingly, ZO-1 mRNA was 68.6% lower in diabetic
renal tissues than innormal control tissues (P<0.05). This
reduction in ZO-1 expression was completely reversed by
PAI-1R treatment (P < 0.05; Fig. 5B).
Collectively, these data suggest that PAI-1R treatment
protects podocyte integrity in diabetic db/db mice by
preserving the expression of slit-diaphram proteins and
counter-regulating pathogenic molecules involved in
podocyte injury.
Study 2: direct effect of PAI-1 on podocyte
injury in vitro
Effect of PAI-1 on mRNA expression of nephrin, ZO-1,
desmin and B7-1 by podocytes. It has been shown that
the therapeutic efficacy of PAI-1R is largely due to
its ability to reduce endogenous activity of PAI-1, by
competion for binding to vitronectin at the site of injury
but lack of protease inhibitory activity (Huang et al.
2006, 2009). In order to delineate the mechanism of
action of PAI-1R further, we examined the direct effect
of PAI-1 in a cultured podocyte model. Based on our
previous studies on cultured mesangial cells (Huang et al.
2006), a recombinant active stable human PAI-1 at the
concentration of 150 nM was chosen. As shown in Fig. 6,
addition of PAI-1 to podocytes for up to 48 h caused
a time-dependent inhibition of both nephrin and ZO-1
mRNA expression. The inhibition at 6 h was 13.4% for
nephrin and 27.2% for ZO-1, and >80% (P < 0.05) at
48 h (Fig. 6A and B). Importantly, these changes seen in
PAI-1-treated podocytes were similar to those observed
in podocytes exposed to 2 ng ml−1 TGFβ1 for 24 h. The
24 h time point was thus used for further experiments as
described below.
A dose-dependent decrease in mRNA levels of both
nephrin and ZO-1 (P < 0.05; Fig. 7A and B) and
a dose-dependent increase in mRNA levels of B7-1
(P < 0.05; Fig. 7D) in podocytes were seen after 24 h of
treatment with PAI-1. While there was also an increase
in mRNA levels of desmin with PAI-1 treatment, the
dose dependence of this phenomenon was less apparent
(Fig. 7C), In comparison, the addition of 2 ng ml−1
TGFβ1 to podocytes for 24 h resulted in dramatic
decreases in both nephrin and ZO-1 mRNA expression
and dramatic increases in both desmin and B7-1 mRNA
expression (P < 0.05 versus normal control for each
comparison). These data indicate that PAI-1 directly alters
gene expressionof podocytemolecules in amanner similar
to TGFβ1.
Effect of PAI-1 on protein production of nephrin, ZO-1 and
B7-1 by podocytes. Consistent with the results onmRNA
expression, 150 nM PAI-1 and 2 ngml−1 TGFβ1 decreased
the protein levels of nephrin and ZO-1 (by 39.4 and 45.4%
for nephrin and 18.7 and 32.0% for ZO-1, respectively;
all P < 0.05; Fig. 8). Meanwhile, both PAI-1 and TGFβ1
significantly increased B7-1 protein production by 230
and 246%, respectively. These results indicate that PAI-1,
similar to TGFβ1, induces podocyte injury by altering
the protein production of normal slit-diaphrammolecules
and B7-1.
Discussion
In the present experiments, we repeatedly observed that
uninephrectomized, diabetic db/db mice developed overt
nephropathy associated with progressive albuminuria and
glomerular mesangial matrix expansion and increased
renal production of fibronectin and collagen at 22weeks of
age.TreatmentwithhumanPAI-1R fromweek20 to22had
no effect on body weight, plasma glucose andHbA1c levels
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but reduced albuminuria and markers of renal fibrosis
seen in db/db mice. Although we have not dissected the
plasmin-dependent and plasmin-independent actions of
PAI-R in the db/db mouse model, we have previously
shown that the effects of PAI-1R on pathological matrix
accumulation in the model of anti-thy-1 nephritis were
completely reversed by tranexamic acid treatment (Huang
et al. 2003, 2006), indicating the plasmin dependence of
these therapeutic actions. In contrast, tranexamic acid had
no effect on other diseasemeasures, including proteinuria,
in an anti-thy-1 nephritis model with PAI-1R treatment
(Huang et al. 2006). This latter observation suggests that
PAI-1Rhas other actions in addition to enhancing plasmin
generation.
Increasing evidence shows that the development
of proteinuria is typically associated with podocyte
foot-process effacement and/or slit-diaphragmdisruption
in proteinuric kidney diseases, including diabetic
nephropathy (Fornoni, 2010).Consistentwith this notion,
untreated diabetic db/db mice in the present study
developed significant segmental podocyte foot-process
effacement associated with reduced renal production
of nephrin, podocin and ZO-1 and increased renal
production of B7-1 and desmin. Importantly, these
changes in podocyte morphology and protein molecules
that are indicative of podocyte injury were all ameliorated
by the treatment with PAI-1R. Nephrin and podocin
are critical for maintaining the barrier function of the
podocyte slit-diaphragm (Liu et al. 2003; Kawachi et al.
2006). Dysfunction or loss of nephrin and podocin may
cause changes in podocyte shape, such as foot-process
effacement, and attenuate the contractile function of
podocytes, leading to detachment from the underlying
GBM (Liu et al. 2003; Kawachi et al. 2006). The PAI-1R
treatment may therefore reduce podocyte injury by
preserving thenormal structureof podocyte foot processes
and slit-diaphragms.
B7-1 is a transmembrane protein normally expressed
on the surface of B lymphocytes and antigen-presenting
cells (Abbas & Sharpe, 1999; Chambers & Allison, 1999).
It has been demonstrated to be synthesized de novo
in podocytes and involved in the disruption of the
slit-diaphragm protein complex and the induction of
foot-process effacement in response to a variety of stress
conditions (Reiser et al. 2004). Thus, B7-1 also acts as an
autocrine factor tomodulate podocyte integrity beyond its
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role in immune cells. Indeed, it has been shown that the
mRNA expression of B7-1 in urinary sediments correlates
with the severity of proteinuria in patients with kidney
diseases (Navarro-Mun˜oz et al. 2011). We observed that
the mRNA expression and protein production of B7-1
were significantly increased indiabetes in the present study
(Figs 4 and 5). However, PAI-1R treatment substantially
reversed the diabetes-induced elevation of B7-1, which
was accompaniedby the recovery of podocytemorphology
and slit-diaphragm protein production and a reduction in
albuminuria.
In addition, podocyte epithelial-to-mesenchymal
transition, characterized by the loss of epithelial markers,
such as ZO-1, and gain of mesenchymal markers, such
as desmin, has been involved in podocyte foot-process
effacement (Li et al. 2008; Yamaguchi et al. 2009). In the
present study, we also observed a reduction in ZO-1 and
an increase in desmin in diabetic renal tissue in db/dbmice
at 22 weeks of age. Treatment with PAI-1R largely reversed
these changes in the signalling molecules of podocyte
epithelial-to-mesenchymal transition. Together, these
results provide evidence that PAI-1Rprotects the podocyte
from injury by counter-regulating the expression profile
of slit-diaphragm proteins and pathogenic molecules in
db/db mice. Consequently, podocyte protection may be
quantified as a marked reduction in albuminuria in the
db/dbmice (Table 2).
In concordance with the protective effect of PAI-1R
on podocyte injury is the notion that PAI-1 directly
regulates podocyte protein expression resulting in cellular
injury and proteinuria. Notably, PAI-1 deletion prevented
diabetic renal complications, including albuminuria, in
both db/db diabetic mice and streptozotocin-induced
diabetic mice (Nicholas et al. 2005; Collins et al. 2006;
Lassila et al. 2007), while transgenic overexpression of
PAI-1 exaggerated proteinuria in a model of immune
nephritis (Kitching et al. 2003), although podocyte
structures were not examined in those animals. In a
mouse model of angiotensin II-mediated hypertensive
kidney disease (Knier et al. 2011), the knockout of
PAI-1 resulted in less glomerulosclerosis. Coincidentally,
more intense nephrin immunostaining was found in the
podocytes. Our present observation in cultured podocytes
provides the first evidence that PAI-1 directly induces
podocyte injury by altering the expression of nephrin
and B7-1, similar to the actions of TGFβ1 (Figs 6–8), a
well-known mediator of podocyte injury (Reiser et al.
2004). In addition, PAI-1 appeared to be sufficient to
induce podocyte epithelial-to-mesenchymal transition in
cell culture by changing the cellular expression of ZO-1
and desmin, similar to the effects of TGFβ1. Collectively,
these observations suggest a newmechanism for the role of
PAI-1 in the pathogenesis of kidney disease via induction
of podocyte injury, in addition to the known injurious
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Figure 8. Effect of PAI-1 on protein production of nephrin, ZO-1 and B7-1 by mouse podocytes
Quiescent mouse podocytes were incubated in the absence (normal control; Con) or the presence of
TGFβ1 (2 ng ml−1) or PAI-1R (150 nmol) for 24 h, and Western blot analysis was performed in cell lysates.
A, representativeWestern blots showing nephrin, ZO-1 and B7-1 protein expression; β-actin was included
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effects of PAI-1 on the matrix degradation (Huang et al.
2006).
The signalling pathway by which PAI-1 directly
modulates podocyte-associated molecules is unclear.
A new signalling pathway in podoctyes that involves
vitronectin, uPAR and αvβ3 integrin has recently
been identified, which leads to podocyte foot-process
effacement and urinary protein loss (Wei et al. 2008).
These findings, together with the ability of PAI-1 to bind
to vitronectin and complex with uPAR through PAI-1
complex formation with uPA, have led to the exciting
possibility that PAI-1 induces podocyte injury through
activation of this uPAR signalling pathway. This further
suggests that the plasmin-independent benefit of PAI-1R
may stem from its inability to interact stably with uPAR,
and thus not activate this signalling pathway.
In conclusion, the present study provides evidence
that, similar to TGFβ1, PAI-1 directly injures podocytes
in diabetes. Reducing the increased PAI-1 activity by
treatment with PAI-1R may, in fact, reduce podocyte
injury, thereby reducing albuminuria. Therefore, PAI-1R
may provide additional therapeutic effect in slowing
the progression of diabetic nephropathy by maintaining
podocyte integrity.
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